ES2065946T3 - Vector que contiene un promotor del gen de la beta-actina de pollo para la expresion de un gen deseado. - Google Patents

Vector que contiene un promotor del gen de la beta-actina de pollo para la expresion de un gen deseado.

Info

Publication number
ES2065946T3
ES2065946T3 ES89111481T ES89111481T ES2065946T3 ES 2065946 T3 ES2065946 T3 ES 2065946T3 ES 89111481 T ES89111481 T ES 89111481T ES 89111481 T ES89111481 T ES 89111481T ES 2065946 T3 ES2065946 T3 ES 2065946T3
Authority
ES
Spain
Prior art keywords
expression
desired gene
gene
vector containing
chicken beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89111481T
Other languages
English (en)
Inventor
Junichi Higashimachi Miyazaki
Ken-Ichi Higashimachi Yamamura
Masatake Araki
Hiroshi Yonemura
Chikateru Nozaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63157569A external-priority patent/JPH025884A/ja
Priority claimed from JP63312444A external-priority patent/JP2824433B2/ja
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of ES2065946T3 publication Critical patent/ES2065946T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN VECTOR DE EXPRESION PARA LA EXPRESION DE UN GEN DESEADO EN UNA CELULA ANIMAL ES DESCRITO, EL VECTOR CONTIENE UN PROMOTOR DEL GEN (BETA)-ACTIN DE GALLINA O UN DERIVADO DEL MISMO Y MAS ABAJO DEL MISMO UN LUGAR PARA LA ENZIMA DE RESTRICCION PARA LA INCORPORACION DE UN GEN DESEADO. ADEMAS SON DESCRITOS LOS CORRESPONDIENTES VECTORES DE EXPRESION RECOMBINADOS, LOS MICROORGANISMOS TRANSFORMADOS Y LOS PROCESOS PARA LA EXPRESION DEL GEN DESEADO EN UNA CELULA HUESPED.
ES89111481T 1988-06-24 1989-06-23 Vector que contiene un promotor del gen de la beta-actina de pollo para la expresion de un gen deseado. Expired - Lifetime ES2065946T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63157569A JPH025884A (ja) 1988-06-24 1988-06-24 ニワトリのβ−アクチン遺伝子プロモーターを組み込んだ外来遺伝子発現プラスミド
JP63312444A JP2824433B2 (ja) 1988-12-09 1988-12-09 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター

Publications (1)

Publication Number Publication Date
ES2065946T3 true ES2065946T3 (es) 1995-03-01

Family

ID=26484966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89111481T Expired - Lifetime ES2065946T3 (es) 1988-06-24 1989-06-23 Vector que contiene un promotor del gen de la beta-actina de pollo para la expresion de un gen deseado.

Country Status (8)

Country Link
US (2) US5811260A (es)
EP (1) EP0351585B1 (es)
KR (1) KR100196741B1 (es)
AT (1) ATE113656T1 (es)
AU (1) AU629554B2 (es)
CA (1) CA1339413C (es)
DE (1) DE68919140T2 (es)
ES (1) ES2065946T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
DE4126484A1 (de) * 1991-08-10 1993-02-11 Bayer Ag Expressionsvektoren und deren verwendung zur darstellung hiv-resistenter menschlicher zellen fuer therapeutische anwendungen
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
WO2000023606A1 (en) 1998-10-22 2000-04-27 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
WO2001033957A1 (fr) * 1999-11-05 2001-05-17 Kyowa Hakko Kogyo Co., Ltd. Mammiferes transgeniques non humains de controle du changement de concentration d'ions calcium dans des cellules
JPWO2004070030A1 (ja) * 2003-02-03 2006-05-25 株式会社イムノ・ジャパン 動物細胞用高発現ベクター
AU2004295590B2 (en) * 2003-12-03 2010-04-29 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter
KR101279677B1 (ko) * 2004-01-22 2013-06-27 가부시키가이샤 디나벡크 겐큐쇼 사이토메갈로바이러스 인핸서 및 닭 β­액틴 프로모터를 포함하는 하이브리드 프로모터를 이용한 마이너스 가닥 ＲＮＡ 바이러스 벡터의 제조방법
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
WO2009064006A1 (ja) 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
JP6059017B2 (ja) 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
CN103874508A (zh) 2011-10-21 2014-06-18 英特维特国际股份有限公司 提供多价免疫的重组非致病性mdv载体
EP3455358B1 (en) * 2016-05-12 2020-08-26 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
TWI779307B (zh) 2019-07-01 2022-10-01 日商衛材R&D企管股份有限公司 抗EphA4抗體

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0174608A1 (en) * 1984-09-13 1986-03-19 The Board Of Trustees Of The Leland Stanford Junior University Beta-actin gene and regulatory elements, preparation and use
US4963481A (en) * 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system

Also Published As

Publication number Publication date
US5811260A (en) 1998-09-22
EP0351585A3 (en) 1990-05-09
DE68919140D1 (de) 1994-12-08
AU629554B2 (en) 1992-10-08
CA1339413C (en) 1997-09-02
EP0351585A2 (en) 1990-01-24
US5770400A (en) 1998-06-23
EP0351585B1 (en) 1994-11-02
DE68919140T2 (de) 1995-03-23
ATE113656T1 (de) 1994-11-15
AU3668389A (en) 1990-01-04
KR910001047A (ko) 1991-01-30
KR100196741B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
ES2065946T3 (es) Vector que contiene un promotor del gen de la beta-actina de pollo para la expresion de un gen deseado.
GB1534822A (en) Dental chairs or like patient supporting devices
ES2061512T3 (es) Polipeptidos de nor-estatina y nor-cicloestatina.
GB2136814B (en) Dna vectors
ES2037752T3 (es) Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
ES8104382A1 (es) Un procedimiento mejorado para isomerizar xilenos
DE3782736T2 (de) Zuchtverfahren fuer leukocyten.
ES2099737T3 (es) Control de microsporogenesis que utilizan secuencias de promotores inducibles del exterior.
ES2058479T3 (es) Compuestos peptidicos.
MX9300059A (es) Promotor y metodo para propporcionar expresion constitutiva de los genes heterologos en un amplio rango de tejidos y organos.
ES2037709T3 (es) Derivados heterociclicos de seis miembros de n,n'-diacilhidrazinas n'-sustituidas.
AR241800A1 (es) Procedimiento para preparar compuestos de eglina y procedimiento para obtener preparados farmaceuticos que incluyan a dichos compuestos de eglina como agente activo.
Higashihara et al. The inhibitory effects of okadaic acid on platelet function
ES2082468T3 (es) Arilalquil esteres del acido 4,5-dihidroxi-9,10-dihidro-9,10-dioxo-2-antracenocarboxilico con actividad terapeutica.
ES2080000B1 (es) Colorantes azo reactivos con las fibras.
AU4210389A (en) Plant elongation factor, promoters, coding sequences and uses
AR245956A1 (es) Vector de adn, cepa bacteriana que lo contiene y metodo para modificar geneticamente una celula vegetal
MX9305375A (es) Procedimiento para la produccion de inhibidores deproteasa.
AR241083A2 (es) Procedimiento para preparar acidos 5-cloro-3-(sustituido)-s-triazol[4,3-a!piridin-7-carboxilicos, utiles como agentes antialergicos
EP0306855A3 (en) Arrangement for loading the parameters into active modules in a computer system
FI864071A (fi) Promoottorijärjestelmä streptomykeettavektoreita varten
DE3563752D1 (en) Compounds having hypolipemizing activity
ES2061652T3 (es) Polipeptidos que contienen homocicloestatina y cicloestatina como agentes antihipertensivos.
GB1213024A (en) Improvements in and relating to load supporting equipment such as for use in mines

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 351585

Country of ref document: ES